Clinical trial

Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

NCT04767698

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Belimumab Normalized identity: belimumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Short-course Ocrelizumab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Continued Ocrelizumab Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2021-10-01

PhasePHASE2

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

BelimumabDRUG · verified · RxNorm: belimumab

Short-course OcrelizumabDRUG

Continued OcrelizumabDRUG

Sponsors & collaborators

Johns Hopkins Universitylead sponsor

GlaxoSmithKlinecollaborator

Mapped research locations

BaltimoreMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04767698 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.